"Whether it's this year or next year, the odds of another economic downturn are high — and growing," Warren says.Politicsread more
A group of gold miners stocks "BAANG" are better plays than mega-cap FAANG names, according to John Roque, technical analyst at Wolfe Research.Marketsread more
Equifax will give consumers a range of options for monitoring their credit or making claims of fraud or data misuse, part of a $425 million restitution fund.Technologyread more
The agreement between the White House and congressional Democrats would raise the debt ceiling for two years and permanently end the sequester.Politicsread more
Microsoft and OpenAI announced a new partnership to build artificial general intelligence to tackle more complex tasks than current AI.Technologyread more
There's a reason the film industry doesn't measure the success of modern movies against those of the past — movie ticket inflation isn't an exact science.Entertainmentread more
A US judge presiding over multidistrict litigation alleging J&J's talc baby powder causes ovarian cancer starts hearing from experts Monday.Health and Scienceread more
Air-conditioner maker Lennox International pointed to colder weather as a key reason for cutting guidance and underperforming in the second quarter.Marketsread more
Following a record breaking opening weekend for Disney's "The Lion King," CNBC's Jim Cramer said the company's stock is an "annunity stream" for investors.Investingread more
The Iranian Intelligence Ministry held a briefing on Monday where they announced the alleged spies were Iranian citizens but trained by the CIA.World Newsread more
Two traders say Boeing's on the path to recovery.Trading Nationread more
With the major pharmaceutical companies done with fourth-quarter earnings, J.P. Morgan is letting clients know which companies look the best down the road.
The group as a whole performed well thanks to strong fundamentals with earnings mostly above expectations, according to analyst Chris Schott.
"Most companies in our coverage reported solid core product trends and in-line/better-than-expected earnings per share, augmented by a greater-than-expected tax benefit," Schott wrote to clients on Wednesday. "Looking forward, with the Major Pharma group still trading at a steep discount to the S&P 500, we see a number of opportunities in the sector."
Schott highlighted the four names J.P. Morgan finds most attractive after the latest earnings season, complete with updates on company performance.
Here are some of the pharma stocks J.P. Morgan has rated overweight.